IL-17与IL-23抑制剂治疗银屑病及银屑病关节炎的不良事件:III期研究的系统综述与Meta分析
该系统综述与Meta分析纳入44篇出版物(43项研究),评估IL-17与IL-23抑制剂治疗银屑病或银屑病关节炎患者在第12、16、24、52周的不良事件发生率。汇总后任何不良事件的比例分别为0.57(95%CI 0.55-0.59)、0.52(95%CI 0.49-0.55)、0.72(95%CI 0.66-0.78)和0.81(95%CI 0.76-0.86)。总体耐受性良好,最常见不良事件为感染、鼻咽炎和头痛。
要点
- IL-17与IL-23抑制剂总体耐受性良好,但不良事件随治疗时间延长而累积增加。
- 最常见不良事件为感染、鼻咽炎和头痛。
- 依奇珠单抗治疗52周时注射部位反应发生率为15.7%。
核心结论
- IL-17与IL-23抑制剂总体耐受性良好,安全性特征较好。
- 研究结果可辅助中重度银屑病患者治疗选择的临床决策。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南。
- 两位作者独立检索PubMed和EMBASE数据库,纳入IL-17与IL-23抑制剂治疗银屑病及银屑病关节炎的III期试验。
- 共纳入44篇出版物(43项研究),采用随机效应模型进行数据合成。
主要发现
- 所有治疗汇总后任何不良事件比例:12周为0.57(95%CI 0.55-0.59),16周为0.52(95%CI 0.49-0.55),24周为0.72(95%CI 0.66-0.78),52周为0.81(95%CI 0.76-0.86)。
- 各治疗中最常见的不良事件为感染、鼻咽炎和头痛。
- 依奇珠单抗治疗52周时注射部位反应发生率为15.7%。
临床怎么用
- 临床选择IL-17或IL-23抑制剂治疗中重度银屑病时,可参考本Meta分析的不良事件发生率数据。
- 需关注治疗过程中感染、鼻咽炎、头痛及注射部位反应等常见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologics targeting interleukin (IL)-17 and IL-23 are generally well-tolerated and considered safe, though adverse events are seen more often compared with placebo. The objectives of this systematic review and meta-analysis were to assess the prevalence of adverse events in patients with psoriasis or psoriatic arthritis with any adverse events after 12, 16, 24 and 52 weeks of treatment with IL-17 or IL-23 inhibitors. Two independent authors searched the databases PubMed and EMBASE for studies reporting on adverse events in phase 3 trials of IL-17 and IL-23 inhibitors for patients with psoriasis and psoriatic arthritis. The study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data synthesis was performed using a random-effects model. In total, 44 publications (43 studies) were included in the analyses. The proportion of patients with any adverse events for all treatments pooled were 0.57 [95% confidence interval (CI): 0.55-0.59] after 12 weeks, 0.52 (95% CI: 0.49-0.55) after 16 weeks, 0.72 (95% CI: 0.66-0.78) after 24 weeks and 0.81 (95% CI: 0.76-0.86) after 52 weeks. Across therapies, the most prevalent AEs were infections, nasopharyngitis and headache. For ixekizumab one of the most prevalent AEs was injection site reactions, reported in 15.7% of the patients after 52 weeks. Overall, IL-17 and IL-23 inhibitors appear to be well-tolerated with good safety profiles. Our findings may aid the clinical decision making when choosing the most appropriate therapy for patients with moderate-to-severe psoriasis.
引用
- Loft ND, Vaengebjerg S, Halling AS, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2019. PMID: 31721310. doi:10.1111/jdv.16073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。